← back to search

Ollivier Hyrien

Fred Hutch Cancer Center ·
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, Stochastic processes and statistical mechanics, and COVID-19 Clinical Research Studies.
h-index
30
citations
3,323
works
159
NIH funding
primary concept
Medicine
email

Recent publications

Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
Science 2025cited by 51position: middledoi
Precise targeting of HIV broadly neutralizing antibody precursors in humans
Science 2025cited by 35position: middledoi
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
Science Translational Medicine 2025cited by 23position: middledoi
Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope
npj Vaccines 2025cited by 1position: middledoi
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
npj Vaccines 2024cited by 39position: middledoi
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies
The Journal of Experimental Medicine 2024cited by 26position: middledoi
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Pharmaceutics 2024cited by 20position: middledoi
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
Nature Communications 2024cited by 20position: middledoi
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
EBioMedicine 2024cited by 16position: middledoi
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
PLoS Medicine 2024cited by 13position: middledoi
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
Nature Communications 2024cited by 12position: middledoi
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
Nature Microbiology 2022cited by 92position: middledoi
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
Annals of Internal Medicine 2021cited by 26position: middledoi
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials
Annals of Internal Medicine 2020cited by 115position: middledoi
Inhibition of Nogo-66 Receptor 1 Enhances Recovery of Cognitive Function after Traumatic Brain Injury in Mice
Journal of Neurotrauma 2012cited by 33position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Leah J. Homad · Fred Hutch Cancer Center1 papers (2025–2025) · 1 papers (2025–2025)Weimin Liu · University of Rochester Medical Center1 papers (2012–2012)Xiaowei Wang · The Eighth Hospital of Xi'an1 papers (2012–2012)A. Davis · Michigan State University1 papers (2025–2025)Uzma Samadani · New York University1 papers (2012–2012)Xiaodi Han · University of Rochester Medical Center1 papers (2012–2012) · 1 papers (2025–2025)Mariane B. Melo · Scripps Research Institute1 papers (2025–2025)Leonidas Stamatatos · Fred Hutch Cancer Center1 papers (2025–2025) · 1 papers (2025–2025)Emilie Seydoux · University of Bern1 papers (2025–2025)Latha Kallur Siddaramaiah · Seattle University1 papers (2025–2025)Douglas H. Smith · Hospital of the University of Pennsylvania1 papers (2012–2012)Jason H. Huang · Baylor University1 papers (2012–2012)Andrew T. McGuire · Fred Hutch Cancer Center1 papers (2025–2025)Jing Tong · Hebei Medical University1 papers (2012–2012)Yu-Hsin Wan · Fred Hutch Cancer Center1 papers (2025–2025)Pia Dosenovic · Rockefeller University1 papers (2025–2025) · 1 papers (2025–2025)